Baharak “Becky” Soltanian has joined the Sanborn Map Co. in Colorado Springs as vice president of research and development. She will be responsible for developing new processes, products and applications
Share this article
Share this article
ENGLEWOOD, Colo., May 10, 2021 /PRNewswire/ Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that it has received Investigational Review Board (IRB) approval to commence enrollment in its AP-018 Phase I study using inhaled Ampion™ with patients exhibiting prolonged respiratory COVID-19 symptoms, known as long (or long-haul) COVID, or Post-Acute Sequelae of SARS-CoV-2. This trial is both needed and exciting in that it addresses a major current and expected ongoing unmet medical need among the estimated 3 to 10 million individuals currently suffering from long COVID, said Michael Macaluso, President and CEO of Ampio.